Acute COPD Exacerbations and In-hospital Treatment-related Problems: An Observational Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jun 6

PMID 38843229

Authors

Oriana Awwad

Rana Abu Farha

Anood Altaharwah

Sarah Sharaya

Abdallah Y Naser

Haya Tabaza

Affiliations

Soon will be listed here.

Abstract

Background: Treatment-related problems (TRPs) interfere with the ability to attain the desired goals of treatment, adding cost to healthcare systems. Patients hospitalized with acute conditions are at particular risk to experience TRPs. Data investigating such burden in patients with acute exacerbation of COPD (AECOPD) is generally scarce with no studies ever conducted in Jordan. This study aimed to investigate and categorize TRPs among patients hospitalized with AECOPD in Jordan, and to estimate their cost savings and cost avoidance.

Methods: This was a retrospective population-based cohort study. Patients' cases of AECOPD admitted to the study site from Jan 2017 to Jul 2021 were identified from the electronic clinical database and screened for eligibility. TRPs were identified/categorized using AbuRuz tool and assessed for their severity. Cost saving was estimated by calculating all the extra costs. Cost avoidance was estimated according to Nesbit method.

Results: A total of 1243 (mean±SD 3.1±1.5) and 503 (mean±SD 1.3±1.2) TRPs were identified during hospitalization and at discharge respectively, of which 49.4% and 66.7% were classified as "unnecessary drug therapy". In 54.5% of the cases, systemic corticosteroid was administered for a period longer than recommended. Most of the TRPs were of moderate severity. The total direct cost saving, and cost avoidance were estimated to be 15,745.7 USD and 340,455.5 USD respectively.

Conclusion: The prevalence and cost of TRPs among AECOPD patients is a concern requiring attention. The study results implicate integrating interventions such as embracing clinical pharmacists' role in the respiratory care units to optimize patients' management.

Citing Articles

A retrospective analysis of the pharmacovigilance data registry in a tertiary teaching hospital in Jordan.

Hammour K, El-Dahiyat F, Hyari R, Salameh S, Manaseer Q, Farha R J Pharm Policy Pract. 2024; 17(1):2378461.

PMID: 39049906 PMC: 11268214. DOI: 10.1080/20523211.2024.2378461.

References

Aburuz S, Bulatova N, Yousef A . Validation of a comprehensive classification tool for treatment-related problems. Pharm World Sci. 2006; 28(4):222-32. DOI: 10.1007/s11096-006-9048-0. View

Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C . Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018; 11(11):1123-1134. DOI: 10.1080/17512433.2018.1531703. View

Ernst F, Grizzle A . Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001; 41(2):192-9. DOI: 10.1016/s1086-5802(16)31229-3. View

Giuliano C, Wilhelm S, Kale-Pradhan P . Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012; 5(3):337-44. DOI: 10.1586/ecp.12.20. View

Rastoder E, Sivapalan P, Eklof J, Saeed M, Svorre Jordan A, Meteran H . Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. Biomedicines. 2021; 9(8). PMC: 8389624. DOI: 10.3390/biomedicines9080874. View

Ni X, Yang C, Bai Y, Hu Z, Zhang L . Drug-Related Problems of Patients in Primary Health Care Institutions: A Systematic Review. Front Pharmacol. 2021; 12:698907. PMC: 8418140. DOI: 10.3389/fphar.2021.698907. View

Zhu Y, Liu C, Zhang Y, Shi Q, Kong Y, Wang M . Identification and resolution of drug-related problems in a tertiary hospital respiratory unit in China. Int J Clin Pharm. 2019; 41(6):1570-1577. DOI: 10.1007/s11096-019-00922-3. View

Leape L, Cullen D, Clapp M, Burdick E, Demonaco H, Erickson J . Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282(3):267-70. DOI: 10.1001/jama.282.3.267. View

Hammad E, Qudah R, Akour A . The impact of clinical pharmacists in improving Jordanian patients' health outcomes. Saudi Med J. 2017; 38(11):1077-1089. PMC: 5767609. DOI: 10.15537/smj.2017.11.21453. View

10.

Classen D, Pestotnik S, Evans R, Lloyd J, Burke J . Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277(4):301-6. View

11.

Chen C, Hsiao F, Shen L, Wu C . The cost-saving effect and prevention of medication errors by clinical pharmacist intervention in a nephrology unit. Medicine (Baltimore). 2017; 96(34):e7883. PMC: 5572025. DOI: 10.1097/MD.0000000000007883. View

12.

Castillo J, Peters S, Busse W . Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017; 5(4):918-927. PMC: 5950727. DOI: 10.1016/j.jaip.2017.05.001. View

13.

Aburuz S, Bulatova N, Yousef A, Al-Ghazawi M, Alawwa I, Al-Saleh A . Comprehensive assessment of treatment related problems in hospitalized medicine patients in Jordan. Int J Clin Pharm. 2011; 33(3):501-11. DOI: 10.1007/s11096-011-9497-y. View

14.

Apikoglu-Rabus S, Yesilyaprak G, Izzettin F . Drug-related problems and pharmacist interventions in a cohort of patients with asthma and chronic obstructive pulmonary disease. Respir Med. 2016; 120:109-115. DOI: 10.1016/j.rmed.2016.10.006. View

15.

Laheij R, Sturkenboom M, Hassing R, Dieleman J, Stricker B, Jansen J . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292(16):1955-60. DOI: 10.1001/jama.292.16.1955. View

16.

Johnson J, Bootman J . Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155(18):1949-56. View

17.

. Draft statement on pharmaceutical care. ASHP Council on Professional affairs. American Society of Hospital Pharmacists. Am J Hosp Pharm. 1993; 50(1):126-8. View

18.

Shqeirat M, Hijazi B, Almomani B . Treatment related problems in Jordanian hemodialysis patients. Int J Clin Pharm. 2021; 43(5):1352-1359. DOI: 10.1007/s11096-021-01259-6. View

19.

Nesbit T, Shermock K, Bobek M, Capozzi D, Flores P, Leonard M . Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm. 2001; 58(9):784-90. DOI: 10.1093/ajhp/58.9.784. View

20.

Asaad Assiri G, Shebl N, Mahmoud M, Aloudah N, Grant E, Aljadhey H . What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018; 8(5):e019101. PMC: 5942474. DOI: 10.1136/bmjopen-2017-019101. View